Efficacy and safety of carvedilol in combination with bronchodilators in patients with CHF of ischemic origin and COPD.

Cover Page

Cite item

Full Text

Abstract

Objective. To study the effectiveness of carvedilol, tiotropium bromide and indacaterol in complex therapy on clinical and functional parameters in patients with CHF of ischemic origin in combination with COPD.

Material and methods. The study included 98 patients aged 45–75 years, suffering from CHF II–III FC with post-infarction cardiosclerosis, LV ejection fraction less than 45% and COPD of 2–3 degrees (GOLD). In addition to basic therapy all patients received carvedilol and were divided into 3 groups: tiotropium was administered in the 1st (36 people), indacaterol in the 2nd (32 people), and a combination of tiotropium and indacaterol in the 3rd (30 people). At baseline and after 6 months of follow-up, the clinical condition, exercise tolerance were assessed, the quality of life was assessed using the clinical state rating scale (SHOX) and MRC dyspnea scale, questionnaires of University of Minnesota (MLHFQ) and St. George’s Hospital (SGRQ). EchoCG, 24-hour blood pressure monitoring with simultaneous ECG recording, and spirometry test were performed.

Results. The use of carvedilol in combination with tiotropium and indacaterol (both in mono and in combination) as part of complex therapy of CHF II–III FC of ischemic genesis with COPD is safe and effective: the clinical condition of patients improved, quality of life, frequency and duration of ischemia episodes decreased significantly, significantly increased LVEF, decreased pulmonary hypertension, improved condition of the bronchopulmonary system.

About the authors

Vladimir V. Evdokimov

Moscow State University of Medicine and Dentistry a.n. A.I. Evdokimov

Author for correspondence.
Email: ivanovkb83@yandex.ru
ORCID iD: 0000-0001-9281-579X
SPIN-code: 1202-1991

канд. мед. наук, профессор кафедры клинической функциональной диагностики лечебного факультета

Russian Federation, 20/1, Delegatskaya street, Moscow, 127473

A. G. Evdokimova

Moscow State University of Medicine and Dentistry a.n. A.I. Evdokimov

Email: aevdokimova@rambler.ru
ORCID iD: 0000-0003-3310-0959
SPIN-code: 5133-3771

д-р мед. наук, профессор кафедры внутренних болезней стоматологического факультета

Russian Federation, 20/1, Delegatskaya street, Moscow, 127473

E. N. Yushchuk

Moscow State University of Medicine and Dentistry a.n. A.I. Evdoki

Email: ndlena@mail.ru
ORCID iD: 0000-0003-0065-5624
SPIN-code: 4706-4335

д-р мед. наук, профессор, зав. кафедрой клинической функциональной диагностики лечебного факультета

Russian Federation, 20/1, Delegatskaya street, Moscow, 127473

References

  1. Чучалин А.Г., Айсанов А.З. Хроническая обструктивная болезнь легких и сердечно-сосудистая коморбидность. / Избранные лекции по терапии под редакцией Г.П. Арутюнова. — М., 2017. — 84 с. [Chuchalin AG, Aysanov AZ. Khronicheskaya obstruktivnaya bolezn’ legkikh i serdechno-sosudistaya komorbidnost’. Izbrannyye lektsii po terapii pod red. GP Arutyunova. Moscow; 2017. 84 р. (In Russ).]
  2. Campo G, Pavasini R, Malagu M, et al. Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management. Cardiovasc Drugs Ther. 2015;29(2):147–157. doi: 10.1007/s10557-014-6569-y.
  3. O´Kelly N, Robertson W, Smith J, et al. Short-term outcomes in heart failure patients with chronic obstructive pulmonary disease in the community. World J Cardiol. 2012;4(3):66–71. doi: 10.4330/wjc.v4.i3.66.
  4. Кароли Н.А., Ребров А.П. Коморбидность у больных ХОБЛ: место кардиоваскулярной патологии // Рациональная фармакотерапия в кардиологии. –2009. — Т.5. — №4. — С. 9–16. [Karoli NA, Rebrov AP. Comorbidity in patients with chronic obstructive pulmonary disease: a role of cardiovascular disorders. Rational Pharmacotherapy in Cardiology. 2009;5(4):9–16. (In Russ).] doi: 10.20996/1819-6446-2009-5-4-9-16.
  5. Евдокимов В.В., Евдокимова А.Г., Коваленко Е.В., Радзевич А.Э. Применение карведилола в комплексной терапии хронической сердечной недостаточности у больных ишемической болезнью сердца с хронической обструктивной болезнью легких // Сердечная недостаточность. — 2010. — Т.11. — №2. — С. 89–91. [Yevdokimov VV, Yevdokimova AG, Kovalenko YeV, Radzevich AE. Primeneniye karvedilola v kompleksnoy terapii khronicheskoj serdechnoj nedostatochnosti u bol’nykh ishemicheskoy bolezn’yu serdtsa s khronicheskoy obstruktivnoy bolezn’yu legkikh. Serdechnaya Nedostatochnost’. 2010;11(2):89–91. (In Russ).]
  6. Айсанов З.П., Авдеев С.Н. Архипов В.В., и др. Национальные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких: алгоритм принятия решений // Пульмонология. — 2017. — Т.27. — №1. — С. 13–20. [Aysanov ZP, Avdeyev SN, Arkhipov VV, et al. National clinical guidelines on diagnosis and treatment of chronic obstructive pulmonary disease: a clinical decision-making algorithm. Pul’monologiya. 2017;27(1):13–20. (In Russ).] doi: 10.18093/0869-0189-2017-27-1-13-20.
  7. Мареев В.Ю., Фомин И.В., Агеев Ф.Т., и др. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН) // Сердечная недостаточность. — 2017. — Т.18. — №1. — С. 3–40. [Mareyev VYu, Fomin IV, Ageyev FT, et al. Chronic heart failure (CHF). Serdechnaya nedostatochnost’. 2017;18(1):3–40. (In Russ).] doi: 10.18087/rhfj.2017.1.2346.
  8. Авдеев С.Н. Стратегии профилактики обострений хронической обструктивной болезни легких // Доктор.Ру. — 2017. — №10. — С. 40–48 [Avdeev SN. Prevention strategies for exacerbations of chronic obstructive pulmonary disease. Doctor.Ru. 2017;(10):40–48. (In Russ).]
  9. Княжеская Н.П. Терапия хронической обструктивной болезни легких: возможности индакатерола. // Consilium Medicum. — 2017. — Т.16. — №11. — С. 13–17. [Knyazheskaya NP. COPD therapy: indacaterol possibilities. Cons Med. 2017;16(11):13–17. (In Russ).]
  10. Айсанов З.Р., Новиков Ю.К. Антихолинергические препараты в лечении хронической обструктивной болезни легких // Трудный пациент. — 2015. —Т.10. — №5. — С. 9–13. [Aysanov ZR, Novikov YuK. Anticholinergic agents for treatment of chronic obstructive pulmonary disease. Trudnyi patsient. 2015;10(5):9–13. (In Russ).]
  11. Чучалин В.Г. Хроническая обструктивная болезнь легких и сопутствующие заболевания // Терапевтический архив (архив до 2018 г.). — 2013. — Т.85. — №8. — С. 43–48. [Chuchalin VG. Khronicheskaya obstruktivnaya bolezn’ legkikh i soputstvuyushchie zabolevaniya. Ter arkhiv. 2013;85(8):43–48. (In Russ).]
  12. GOLD report on the diagnosis and management of COPD [Internet]. Prescriber. 2017;28 (Issue 2):28–32 [cited 2017 February 28]. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/psb.1538.
  13. Евдокимов В.В., Коваленко Е.В., Евдокимова А.Г., и др. Особенности структурно-функциональных изменений сердечно-сосудистой системы и их коррекция у пациентов с хронической сердечной недостаточностью в сочетании с кардиопульмональной патологией // CardioСоматика. — 2018. — Т.9. — №1. — С. 32–39. [Yevdokimov VV, Kovalenko YeV, Yevdokimova AG, et al. Features of structural and functional changes in the cardiovascular system and their correction in patients with chronic heart failure in combination with cardiopulmonary pathology. Cardiosomatics. 2018;9(1):32–39. (In Russ).] doi: 10.26442/2221-7185_2018.1.32-39.
  14. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365. doi: 10.1164/rccm.201204-0596PP.
  15. Куценко М.А. Комбинированный бронхолитик длительного действия вилантерол/умеклидиния бромид для лечения ХОБЛ // РМЖ. — 2015. — №18. — С. 1109–1115. [Kutsenko MA. Kombinirovannyye bronkholitiki dlitel’nogo deystviya vilanterol/umeklidiya bromid dlya lecheniya KHOBL. RMZH. 2015;(18):1109–1115. (In Russ).]
  16. Сazzola M, Molimard M. The scientific rationale for combining long-acting β2-agonists and muscarinic in COPD. Pulm Pharmacol Ther. 2010;23(4):257–267. doi: 10.1016/j.pupt.2010.03.003.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Evdokimov V.V., Evdokimova A.G., Yushchuk E.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies